On August 22, 2024, BioNTech SE and Pfizer received FDA approval for their 2024-2025 Omicron KP.2-adapted COVID-19 vaccine for those aged 12 and older, and emergency use authorization for ages 6 months to 11 years. This is a significant event for the company.